Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full NewsPreschool-aged children exposed to screens for extended daily periods face elevated prevalence of sleep disturbances.
Treatment rates for US adults with psychiatric disorders are modestly higher than in previous decades, but only a third receive minimally adequate care, new research shows.
An Australian-designed smartphone app uses personalized cognitive bias modification to help users reduce or avoid alcohol consumption.
In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.
Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.
1.
Germline Variants Predict Lobular Breast Cancer Recurrence
2.
A novel blood test may enable the early identification of common, fatal cancers.
3.
Where Does Mistletoe Extract Fit in Supportive Cancer Care?
4.
Finding a clue to the origin of treatment-resistant leukemia in kids
5.
In myelofibrosis, combinations of rufolitinib reduce spleen volume.
1.
Everything You Need to Know About Normal Potassium Levels
2.
Evidence-Based Approaches in Hematology for Modern Medicine
3.
Synovial Sarcoma of Female Urethra: Case Report and Literature Review
4.
The Latest Research on Chronic Granulomatous Disease and Promising New Treatments
5.
Gene Therapy for Hemophilia: A New Hope on the Horizon
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
Nutrition During Cancer Treatment
2.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
3.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation